Roger Delk

Magellan Medicaid Administration Achieves ISO 9001:2015 Recertification

Retrieved on: 
Wednesday, November 29, 2023
MMA, Roger Delk, Pharmacy, ISO, Health, Ferdinand Magellan, CMS, PBA, Partnership, Poverty, Medicare, ISO 9001:2015, State government, Certification, Audit, Medicaid

EAGAN, Minn., Nov. 29, 2023 /PRNewswire/ -- Prime Therapeutics LLC (Prime) and Magellan Rx announced today that Magellan Medicaid Administration, LLC (MMA), the organization's state government pharmacy benefit administration (PBA) solution, has earned ISO 9001:2015 recertification for the design and delivery of pharmacy benefit administration for government contracts.

Key Points: 
  • EAGAN, Minn., Nov. 29, 2023 /PRNewswire/ -- Prime Therapeutics LLC (Prime) and Magellan Rx announced today that Magellan Medicaid Administration, LLC (MMA), the organization's state government pharmacy benefit administration (PBA) solution, has earned ISO 9001:2015 recertification for the design and delivery of pharmacy benefit administration for government contracts.
  • Delk added, "MMA is an industry leader in Medicaid pharmacy programs and delivers a best-in-class health care experience for our state partners.
  • Magellan Medicaid Administration has over 39 years of PBA experience and currently services programs for 28 states and the District of Columbia.
  • The ISO 9001:2015 certification covers all MMA clients and locations and is internationally recognized across all industries.

Magellan Rx Management releases new report, "The State of Value-based Contracting (VBC): Reinventing the Current Drug Payment Model in Medicaid"

Retrieved on: 
Thursday, August 24, 2023
CGT, Face, Disability, VBC, Negotiation, Patient, VBC-90, Roger Delk, Cell, Federation, Pharmaceutical industry, Health insurance, Medicaid

EAGAN, Minn., Aug. 24, 2023 /PRNewswire/ -- Magellan Rx Management (Magellan Rx), a Prime Therapeutics (Prime) company, today published a new Medicaid Pharmacy Insights report examining the current drug payment model in Medicaid, and the emerging budgetary challenges of new, multi-million dollar cell and gene therapies (CGT). The report illustrates the unique barriers facing state Medicaid programs and introduces Value Plus, the first multi-state value-based contracting (VBC) solution designed to assist state Medicaid programs in securing access to CGT for patients while helping to ensure the cost of therapy is linked to the value it promises to deliver.

Key Points: 
  • Unlike most traditional treatments, CGT are viewed as one-time therapies intended to cure or significantly alter the trajectory of a person's disease.
  • Cell therapies are typically priced close to $500,000 per treatment while gene therapies often exceed $1 million per treatment.
  • As illustrated in the report, these ultra-high-cost therapies have the potential to disrupt state Medicaid budget models, creating financial exposure for states.
  • Accordingly, existing pharmaceutical purchasing models must be reinvented to address the costs of these breakthrough therapies while preserving access to care.

"KANSAS CITY WILL REVOLUTIONIZE AI," SAYS TORCH.AI CHIEF PRODUCT OFFICER JASON DELKER

Retrieved on: 
Friday, March 4, 2022
Nexus, Risk, Intelligence, American Century, Machine learning, View, Cerner, DST, Organization, VML, Solution, Growth, T-Mobile, Goal, Multimedia, IOT, Fraud, Torch, Marketing, CEO, Roger Delk, Environment, AI, Technology, D.C, Trust, Medical device, Management, Online shopping, Garmin, Kansas City metropolitan area, Sprint

LEAWOOD, Kan., March 4, 2022 /PRNewswire/ -- "The unique dynamics of the Kansas City region are paving the way for a new era of machine learning," says Jason "Delk" Delker, Torch.AI's new Chief Product Officer, a technology pioneer responsible for more than 150 patents.

Key Points: 
  • LEAWOOD, Kan., March 4, 2022 /PRNewswire/ -- "The unique dynamics of the Kansas City region are paving the way for a new era of machine learning," says Jason "Delk" Delker, Torch.AI's new Chief Product Officer, a technology pioneer responsible for more than 150 patents.
  • "I've been fortunate throughout my career to be on the frontlines of product innovation," said Delk.
  • "He is a powerhouse blend of creative product development genius and data aficionado, making him the ideal fit to lead our product team.
  • To learn more about the company's vision for unifying AI, visit the website at Torch.AI
    View original content to download multimedia: https://www.prnewswire.com/news-releases/kansas-city-will-revolutionize-...

Long Predicted Medicaid Specialty Drug Trend Finally Surpasses 50% of Pharmacy Spend in the Latest Magellan Rx Management Medicaid Pharmacy Trend Report

Retrieved on: 
Monday, November 15, 2021
Professional Services, Health, Insurance, Managed Care, General Health, Pharmaceutical, MGLN, Industry, Roger Delk, Government, HIV/AIDS, Economics, Pharmacy, Health, NASDAQ, FFS, Technology, Forecasting, Lists of Star Trek episodes, PBA, COVID-19, Magellan Health, Solution, MSW, Ferdinand Magellan, Trade, Patient, District, Hospital, Pharmaceutical industry, Magellan Rx Management, Magellan Health:, MAGELLAN RX MANAGEMENT, MAGELLAN HEALTH:

Magellan Rx Management , the full-service pharmacy benefits management division of Magellan Health, Inc. (NASDAQ: MGLN), released its sixth annual Medicaid Pharmacy Trend ReportTM , the industry's leading report exclusively detailing trends in the Medicaid pharmacy fee-for-service (FFS) space.

Key Points: 
  • Magellan Rx Management , the full-service pharmacy benefits management division of Magellan Health, Inc. (NASDAQ: MGLN), released its sixth annual Medicaid Pharmacy Trend ReportTM , the industry's leading report exclusively detailing trends in the Medicaid pharmacy fee-for-service (FFS) space.
  • The Medicaid Pharmacy Trend Report highlights the evolving landscape of Medicaid, made even more dynamic from the events of the last two years.
  • The Magellan Rx Management Medicaid Pharmacy Trend Report includes data from Magellan Rx's Medicaid FFS pharmacy programs in 25 states and the District of Columbia.
  • About Magellan Rx Management: Magellan Rx Management , a division of Magellan Health, Inc., is shaping the future of pharmacy.